WO1990010710A1 - Detection of pyrogens by recombinant mammalian cells - Google Patents

Detection of pyrogens by recombinant mammalian cells Download PDF

Info

Publication number
WO1990010710A1
WO1990010710A1 PCT/GB1990/000312 GB9000312W WO9010710A1 WO 1990010710 A1 WO1990010710 A1 WO 1990010710A1 GB 9000312 W GB9000312 W GB 9000312W WO 9010710 A1 WO9010710 A1 WO 9010710A1
Authority
WO
WIPO (PCT)
Prior art keywords
cell line
promoter
coding region
galactosidase
pyrogen
Prior art date
Application number
PCT/GB1990/000312
Other languages
French (fr)
Inventor
Enda Kenny
Original Assignee
Delta Biotechnology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Limited filed Critical Delta Biotechnology Limited
Publication of WO1990010710A1 publication Critical patent/WO1990010710A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Definitions

  • This invention relates to assay systems for pyrogenic molecules which exert their effects through the transcriptional activation of genes.
  • assay of such compounds may involve the treatment of specific mammalian cell lines with the test substance and the subsequent assay of the cell line for synthesis of the gene product known to be produced in response to the test agent.
  • the assay and quantitation of the newly synthesised gene product in such a system is then an indicator of the amount of active material in the test substance.
  • LPS lipopolysaccharide
  • the currently accepted methods for detecting pyrogens are the Limulus Amoebocyte Lysate (LAL) and the rabbit test.
  • LAL test is an in vitro test whilst the rabbit test directly measures the rise in body temperature in response to injection of the test substance.
  • the febrile response is mediated by the release from monocytes of cytokines, such as tumour necrosis factor and interleukin 1 , which have a broad- range of biological effects.
  • cytokines such as tumour necrosis factor and interleukin 1
  • a refinement of the pyrogen test is the direct measurement of cytokines released by monocytes in vitro using immuno methods.
  • the synthesis and release of both TNF and interleukin-1 by monocytes following treatment with LPS are well characterised (Dinarello, 1984; Phillip and Epstein, 1986) and a monocyte test for pyrogen has been developed based on these observations (Poole, et al. , 1988).
  • interleukin 1 At least two distinct forms of interleukin 1 exist, termed IL-l ⁇ and IL-l ⁇ (March, et al. , 1985). Of these, the IL-l ⁇ gene is more responsive to LPS stimulation (Poole, et al. , 1988). Established monocytic cell lines are similarly responsive to LPS although the sensitivity of such cell lines is reportedly not as great as that of fresh monocyte preparations (Poole, et al. , 1988). Such detection methods, however, may be laborious and require the use of expensive reagents and equipment.
  • one aspect of the present invention provides a mammalian cell line having an inheritable genetic element comprising a TNF, IL-l ⁇ or IL-l ⁇ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
  • promoter means a nucleotide sequence 5' to a TNF, IL-l ⁇ or IL-l ⁇ coding region which controls transcription thereof; the promoter may comprise an enhancer system which may or may not be one normally associated with that promoter.
  • reporter polypeptide is used to mean a polypeptide other than TNF, IL-l ⁇ or IL-l ⁇ and which polypeptide can be detected by means other than (i) immunological techniques and (ii) means requiring a second living cell.
  • a second aspect of the invention provides an assay system comprising a cell line having an inheritable genetic element comprising a TNF, IL-l ⁇ or IL-l ⁇ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
  • a third aspect of the invention provides a vector for transfecting a cell line, the vector comprising a TNF, IL-l ⁇ or IL-l ⁇ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
  • the cell line is derived from a human blood monocyte, such as the THP-1 and U937 cell lines.
  • the promoter is human-derived.
  • the reporter polypeptide is conveniently ⁇ -galactosidase, chloramphenicol acetyl transferase, luciferase, phosphatase or ⁇ -galactosidase.
  • Transcriptional and translational start and stop codons and downstream regulatory regions may be included as necessary and in known ways.
  • Figure 1 shows the partial sequence of the IL-l ⁇ gene (from Bensi et al, 1987), with the exons boxed and the positions at which probes 1 and 2 hybridize also indicated;
  • Figure 2 illustrates schematically the subcloning of the IL-l ⁇ promoter into plasmid ml3mp8 to form plasmid mp8.1;
  • Figure 3 illustrates schematically the site-directed mutagenesis of plasmid mp8.1 to give plasmid mp ⁇ .1.1;
  • Figure 4 illustrates schematically the construction of plasmid pEK007.
  • EXAMPLE 1 A CELL LINE FOR DETECTION OF INTERLEUKIN l ⁇ SYNTHESIS
  • the IL-l ⁇ gene promoter is fused to the lacZ gene of E.coli which encodes ⁇ -galactosidase and this cassette is inserted into a suitable cell line. Stimulation of this cell line by LPS or other pyrogen will result in the synthesis of ⁇ -galactosidase which may then be detected in a simple colorimetric assay. Thus pyrogen may be measured indirectly, obviating the requirement for the relatively complex, time consuming and expensive immunological techniques used in the direct detection of TNF and IL-l ⁇ . The construction of such a cell line is given below. The molecular biological techniques are generally those taught by Maniatis et al, 1982.
  • a human leukocyte genomic DNA bank in the vector EMBL3 may be obtained from Clontech Laboratories Inc. (Palo Alto, California).
  • the sequence of the 5' end of the IL-l ⁇ gene is shown in Figure 1 (Bensi et al. , 1987).
  • Oligonucleo ide probes which hybridize to the positions underlined in Figure 1 are constructed on an automatic DNA synthesiser using phosphoramidite chemistry and reagents supplied by the manufacturer (Applied Biosystems, Foster City, California). These structures are as follows:
  • oligonucleotides are labelled with ⁇ 2 P and used to probe the gene bank by plaque hybridization as described by Maniatis et al. , (1982).
  • Positive clones those hybridizing to both primers, are further characterized by restriction mapping and comparison with the published restriction data available via analysis of the DNA sequence described previously (Bensi et al. , 1987). In this way the sequence may be extended 5' to that reported by Bensi et a ⁇ (1987) and the upstream sequence encompassing the promoter or regulatory regions isolated. This is most probably located in a region extending to 3kb 5' from the transcription start site.
  • the insert or partial insert of the EMBL-3 clone which spans the desired sequence is subcloned into M13mp8 (Messing, 1983).
  • mp8.1 is manipulated to create a Bglll site in exon 2 which is compatible with the tailored ⁇ -galactosidase gene from plasmid pMC1924 (Nielsen et al, 1983). This is most readily carried out by changing two nucleotides in exon 2 as shown in Fig 3 using the technique of oligonucleotide-directed mutagenesis (Zoller and Smith, 1983) to create x ⁇ p ⁇ .l.l.
  • the lL-l ⁇ promoter-N-terminus is now located on a Smal-Bglll fragment, the Smal site being derived from M13mp8. This fragment is then cloned into PvuII/BamHI digested pMC1924 (Nielsen et al, 1983) to give the plasmid pEK007 (Fig 4).
  • the E. coli ⁇ -galactosidase gene has been tailored in pMC1924 such that insertion of the above fragment will result in an in- frame fusion of the IL-l ⁇ -N-terminus and ⁇ -galactosidase.
  • the fusion will have ⁇ -galactosidase enzyme activity.
  • the recombinant pMC1924 derivative containing the interleukin-l ⁇ promoter, pEK007, is next transferred into a suitable cell line such as THP-1 (Fenton, et al. , 1987) as described by Gorman (1985).
  • Stable integrant clones are obtained via co- transfection of pSVNeo, encoding resistance to the aminoglycoside G418 (Southern and Berg, 1982).
  • Co-integrants of pSVNeo and pEK007 are screened for by resistance to G418 and subsequent Southern blotting of G418 resistance clones for co- insertion of the ⁇ -galactosidase gene using the ⁇ -galactosidase gene as a probe, as described by Maniatis et al. , (1982).
  • the transgenic THP-1 cell line is next induced with LPS as described in Fenton et al. (1987).
  • ⁇ -galactosidase may be assayed as described by Gorman (1985) and Nielsen (1983). Analysis of LPS-stimulated clones shows that ⁇ -galactosidase is produced and the amount produced corresponds with the degree of stimulation. It is probable that cell lines with different copy numbers of integrated pEK007 will exhibit slightly different responses, with the degree of responsiveness and thus sensitivity being proportional to the number of integrated copies of the plasmid. Following these analyses, a suitable sub-line is chosen as the basis for the pyrogen assay and its response to a range of pyrogens in addition to LPS assessed. Additional Expression Signals
  • Some mammalian and higher eukaryotic genes have additional expression regulatory elements within the gene itself or in the 3' non-coding region. There may well be such additional elements within the interleukin l ⁇ gene. Thus expression of the hybrid interleukin I ⁇ : ⁇ -galactosidase fusion polypeptide may require such additional signals. If therefore LPS failed to stimulate ⁇ -galactosidase synthesis, selected regions such as the 3' non-coding region of the interleukin l ⁇ gene may be attached to the fusion and the effect of these assessed.
  • a typical assay kit using a cell line of the invention may be supplied as a microtitre plate containing a sample of the cell line and the substrate for ⁇ -galactosidase (X-gal) in each well along with cell culture medium and other essential factors.
  • the plate may be supplied frozen and would be thawed prior to use and addition of the test sample to the culture dish well. Incubation at 37°C in a suitable incubator will proceed for a period of time sufficient for the pyrogen contained with the test sample to stimulate ⁇ -galactosidase expression and sufficient chromophore to be generated to facilitate its measurement in a plate-reading spectrophotometer.
  • the signal generated may finally be compared to that generated by known amounts of pyrogen in a parallel standard assay and thus the amount of pyrogen in the test sample assessed.
  • TNF and IL-l ⁇ gene promoters are alternative promoters in this system.
  • TNF and IL-l ⁇ gene promoters are alternative promoters in this system.
  • simple reporter genes such as chloramphenicol acetyl transferase (CAT), horseradish peroxidase, luciferase and phosphatase which may be substituted for ⁇ -galactosidase to facilitate detection of cytokine synthesis.
  • CAT chloramphenicol acetyl transferase
  • horseradish peroxidase luciferase
  • phosphatase which may be substituted for ⁇ -galactosidase to facilitate detection of cytokine synthesis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

A mammalian cell line having an inheritable genetic element comprising a TNF, IL-1α or IL-1β promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide. The cell line is used as the basis of an assay. The promoter is preferably the human interleukin-1α or -1β promoter, the cell line is preferably human monocyte derived, and the reporter polypeptide may be β-galactosidase, α-galactosidase, chloramphenicol acetyl transferase, luciferase or phosphatase.

Description

DETECTION OF PYROGENS BY RECOMBINANT MAMMALIAN CELLS
This invention relates to assay systems for pyrogenic molecules which exert their effects through the transcriptional activation of genes.
At present, assay of such compounds may involve the treatment of specific mammalian cell lines with the test substance and the subsequent assay of the cell line for synthesis of the gene product known to be produced in response to the test agent. The assay and quantitation of the newly synthesised gene product in such a system is then an indicator of the amount of active material in the test substance.
Microbial contamination of parenterally administered therapeutic products commonly results in a pyrogenic reaction upon administration. Man is particularly sensitive to bacterial lipopolysaccharide (LPS) which, in even nanogram amounts, may induce fever. Pharmaceutical products which are intended for parenteral administration must therefore be screened for pyrogenic contaminants. The currently accepted methods for detecting pyrogens are the Limulus Amoebocyte Lysate (LAL) and the rabbit test. The LAL test is an in vitro test whilst the rabbit test directly measures the rise in body temperature in response to injection of the test substance. However, these tests are not definitive and at least one case of an E.coli derived recombinant product has been reported which was pyrogen negative in the above tests but which upon administration to man proved to be pyrogenic (Dinarello, et al. , 1985).
The febrile response is mediated by the release from monocytes of cytokines, such as tumour necrosis factor and interleukin 1 , which have a broad- range of biological effects. A refinement of the pyrogen test is the direct measurement of cytokines released by monocytes in vitro using immuno methods. The synthesis and release of both TNF and interleukin-1 by monocytes following treatment with LPS are well characterised (Dinarello, 1984; Phillip and Epstein, 1986) and a monocyte test for pyrogen has been developed based on these observations (Poole, et al. , 1988).
At least two distinct forms of interleukin 1 exist, termed IL-lα and IL-lβ (March, et al. , 1985). Of these, the IL-lβ gene is more responsive to LPS stimulation (Poole, et al. , 1988). Established monocytic cell lines are similarly responsive to LPS although the sensitivity of such cell lines is reportedly not as great as that of fresh monocyte preparations (Poole, et al. , 1988). Such detection methods, however, may be laborious and require the use of expensive reagents and equipment.
We have now found that such potential problems may be reduced by the replacement of the known induced gene product with an easily quantifiable reporter gene within the mammalian or other cell line normally used for assay. Thus the reporter gene is induced in response to the test sample and then easily quantified as outlined in the description following. Additionally, such new cell lines can have the advantage of increased sensitivity since response is proportional to the copy number of the cloned promoter-reporter gene fusion and this copy number can be made to be more than one.
Thus, one aspect of the present invention provides a mammalian cell line having an inheritable genetic element comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
As used herein, the term "promoter" means a nucleotide sequence 5' to a TNF, IL-lα or IL-lβ coding region which controls transcription thereof; the promoter may comprise an enhancer system which may or may not be one normally associated with that promoter. The term "reporter polypeptide" is used to mean a polypeptide other than TNF, IL-lα or IL-lβ and which polypeptide can be detected by means other than (i) immunological techniques and (ii) means requiring a second living cell. A second aspect of the invention provides an assay system comprising a cell line having an inheritable genetic element comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
A third aspect of the invention provides a vector for transfecting a cell line, the vector comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
In a preferred embodiment of the invention, the cell line is derived from a human blood monocyte, such as the THP-1 and U937 cell lines. Preferably, the promoter is human-derived.
The reporter polypeptide is conveniently β-galactosidase, chloramphenicol acetyl transferase, luciferase, phosphatase or α-galactosidase. Transcriptional and translational start and stop codons and downstream regulatory regions may be included as necessary and in known ways.
Preferred embodiments of the present invention will now be described by way of example and with reference to the accompanying drawings, in which:
Figure 1 shows the partial sequence of the IL-lβ gene (from Bensi et al, 1987), with the exons boxed and the positions at which probes 1 and 2 hybridize also indicated;
Figure 2 illustrates schematically the subcloning of the IL-lβ promoter into plasmid ml3mp8 to form plasmid mp8.1;
Figure 3 illustrates schematically the site-directed mutagenesis of plasmid mp8.1 to give plasmid mpδ.1.1; and
Figure 4 illustrates schematically the construction of plasmid pEK007.
EXAMPLE 1 : A CELL LINE FOR DETECTION OF INTERLEUKIN lβ SYNTHESIS
Outline
The IL-lβ gene promoter is fused to the lacZ gene of E.coli which encodes β-galactosidase and this cassette is inserted into a suitable cell line. Stimulation of this cell line by LPS or other pyrogen will result in the synthesis of β-galactosidase which may then be detected in a simple colorimetric assay. Thus pyrogen may be measured indirectly, obviating the requirement for the relatively complex, time consuming and expensive immunological techniques used in the direct detection of TNF and IL-lβ. The construction of such a cell line is given below. The molecular biological techniques are generally those taught by Maniatis et al, 1982.
Isolation of the IL-lβ Gene Promoter
A human leukocyte genomic DNA bank in the vector EMBL3 may be obtained from Clontech Laboratories Inc. (Palo Alto, California). The sequence of the 5' end of the IL-lβ gene is shown in Figure 1 (Bensi et al. , 1987). Oligonucleo ide probes which hybridize to the positions underlined in Figure 1 are constructed on an automatic DNA synthesiser using phosphoramidite chemistry and reagents supplied by the manufacturer (Applied Biosystems, Foster City, California). These structures are as follows:
Probe 1
G A C C A C A T T A A A A T A C T G G A T T T T C C C A C G
Probe 2
C A G G T A C T T C T G C C A T G G C T G C T T C A G A C A C
These oligonucleotides are labelled with ^2P and used to probe the gene bank by plaque hybridization as described by Maniatis et al. , (1982).
Positive clones, those hybridizing to both primers, are further characterized by restriction mapping and comparison with the published restriction data available via analysis of the DNA sequence described previously (Bensi et al. , 1987). In this way the sequence may be extended 5' to that reported by Bensi et a^ (1987) and the upstream sequence encompassing the promoter or regulatory regions isolated. This is most probably located in a region extending to 3kb 5' from the transcription start site. Next the insert or partial insert of the EMBL-3 clone which spans the desired sequence is subcloned into M13mp8 (Messing, 1983). This is carried out by insertion of a blunt-ended DNA fragment into the BamHI site of M13mp8 which has been similarly blunt-ended as described previously (GB-A-2175590) as shown in Fig 2. A clone (designated mp8.1) is chosen in which exon 2 is adjacent to the Sail site of mp8.
Next, mp8.1 is manipulated to create a Bglll site in exon 2 which is compatible with the tailored β-galactosidase gene from plasmid pMC1924 (Nielsen et al, 1983). This is most readily carried out by changing two nucleotides in exon 2 as shown in Fig 3 using the technique of oligonucleotide-directed mutagenesis (Zoller and Smith, 1983) to create xαpδ.l.l.
The lL-lβ promoter-N-terminus is now located on a Smal-Bglll fragment, the Smal site being derived from M13mp8. This fragment is then cloned into PvuII/BamHI digested pMC1924 (Nielsen et al, 1983) to give the plasmid pEK007 (Fig 4).
The E. coli β-galactosidase gene has been tailored in pMC1924 such that insertion of the above fragment will result in an in- frame fusion of the IL-lβ-N-terminus and β-galactosidase. The fusion will have β-galactosidase enzyme activity. Transfection of Cell Line
The recombinant pMC1924 derivative containing the interleukin-lβ promoter, pEK007, is next transferred into a suitable cell line such as THP-1 (Fenton, et al. , 1987) as described by Gorman (1985). Stable integrant clones are obtained via co- transfection of pSVNeo, encoding resistance to the aminoglycoside G418 (Southern and Berg, 1982). Co-integrants of pSVNeo and pEK007 are screened for by resistance to G418 and subsequent Southern blotting of G418 resistance clones for co- insertion of the β-galactosidase gene using the β-galactosidase gene as a probe, as described by Maniatis et al. , (1982).
Induction of β-Galactosidase Synthesis
The transgenic THP-1 cell line is next induced with LPS as described in Fenton et al. (1987). β-galactosidase may be assayed as described by Gorman (1985) and Nielsen (1983). Analysis of LPS-stimulated clones shows that β-galactosidase is produced and the amount produced corresponds with the degree of stimulation. It is probable that cell lines with different copy numbers of integrated pEK007 will exhibit slightly different responses, with the degree of responsiveness and thus sensitivity being proportional to the number of integrated copies of the plasmid. Following these analyses, a suitable sub-line is chosen as the basis for the pyrogen assay and its response to a range of pyrogens in addition to LPS assessed. Additional Expression Signals
Some mammalian and higher eukaryotic genes have additional expression regulatory elements within the gene itself or in the 3' non-coding region. There may well be such additional elements within the interleukin lβ gene. Thus expression of the hybrid interleukin Iβ:β-galactosidase fusion polypeptide may require such additional signals. If therefore LPS failed to stimulate β-galactosidase synthesis, selected regions such as the 3' non-coding region of the interleukin lβ gene may be attached to the fusion and the effect of these assessed.
A typical assay kit using a cell line of the invention may be supplied as a microtitre plate containing a sample of the cell line and the substrate for β-galactosidase (X-gal) in each well along with cell culture medium and other essential factors. The plate may be supplied frozen and would be thawed prior to use and addition of the test sample to the culture dish well. Incubation at 37°C in a suitable incubator will proceed for a period of time sufficient for the pyrogen contained with the test sample to stimulate β-galactosidase expression and sufficient chromophore to be generated to facilitate its measurement in a plate-reading spectrophotometer. The signal generated may finally be compared to that generated by known amounts of pyrogen in a parallel standard assay and thus the amount of pyrogen in the test sample assessed. FURTHER EXAMPLES
Alternative Promoters and Reporter Genes
The effector cytokines for the pyrogenic response are believed to be TNF, IL-lβ and IL-lα; however additional factors may be involved. Thus, TNF and IL-lα gene promoters are alternative promoters in this system. Similarly there are other simple reporter genes such as chloramphenicol acetyl transferase (CAT), horseradish peroxidase, luciferase and phosphatase which may be substituted for β-galactosidase to facilitate detection of cytokine synthesis. Gorman (1985), section 7.1, details an assay for CAT, whilst Van Zonneveld et al (1988) detail an assay for luciferase.
REFERENCES
Bensi, G. , et al. , (1987) Gene, 52; 95-101.
Dinarello, CA. (1984) Rev.Infect.Pis. 6; 51-95.
Dinarello, CA. , et al. , (1985) J.Clin.Microbiol, 20; 323-329.
Fenton, M.J., et al. , (1987) J.Immunol, 138; 3972-3979.
Gorman, C (1985) in "DNA Cloning Vol II". Glover, D.M. (Ed) 143-189 IRL Press Oxford.
Maniatis, T. , et al. , (1982) Molecular Cloning : A laboratory- manual. Cold Spring Harbor Publications, N.Y. U.S.A.
March, C.J. et al. , (1985) Nature. 315; 641-647.
Messing, J. (1983) Methods in Enzymol. 100, 20-78.
Nielsen, D.A. , et al. , (1983) Proc. Natl. Acad. Sci (USA). 80; 5198-5202.
Phillip, R. and Epstein, L. (1986) Nature. 323, 86-89.
Poole, S., et al. , (1988) Lancet. I, 130. Van Zonneveld, A-J. , Curriden, S.A. and Loskutoff, D.J. (1988) Proc. Natl. Acad. Sci. USA. 85; 5525-5529.
Zoller, M.J. and Smith M. (1983) Methods in Enzymol. 100; 468- 500.

Claims

1. A mammalian cell line having an inheritable genetic element comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
2. A cell line according to Claim 1 wherein the cell line is adapted to detect the presence of microbial endotoxin.
3. A cell line according to Claim 1 or 2 wherein the cell line is derived from a monocyte.
4. A cell line according to any one of the preceding claims wherein the promoter is human derived.
5. A cell line according to any one of the preceding claims wherein the reporter polypeptide is β-galactosidase, chloramphenicol acetyl transferase, luciferase, a phosphatase or α-galactosidase.
6. An assay system comprising a cell line according to any one of the preceding claims.
7. A vector for transfecting a cell line, the vector comprising a TNF, IL-lα or IL-lβ promoter and, under transcriptional control thereof, a coding region, wherein the promoter controls transcription of the coding region in response to the exposure of the said cell line to a pyrogen and the said coding region encodes a reporter polypeptide.
PCT/GB1990/000312 1989-03-09 1990-02-28 Detection of pyrogens by recombinant mammalian cells WO1990010710A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8905394.6 1989-03-09
GB898905394A GB8905394D0 (en) 1989-03-09 1989-03-09 Detection of certain molecules

Publications (1)

Publication Number Publication Date
WO1990010710A1 true WO1990010710A1 (en) 1990-09-20

Family

ID=10653014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1990/000312 WO1990010710A1 (en) 1989-03-09 1990-02-28 Detection of pyrogens by recombinant mammalian cells

Country Status (5)

Country Link
AU (1) AU5160690A (en)
CA (1) CA2011799A1 (en)
GB (1) GB8905394D0 (en)
IL (1) IL93592A0 (en)
WO (1) WO1990010710A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496027A1 (en) * 1991-01-25 1992-07-29 R.O.B.I.T. RESEARCH AND DEVELOPMENT COMPANY LTD., c/o EFRATI, GALILI & CO. A bioluminescence assay for gene expression in growing mammalian cells
EP0516443A1 (en) * 1991-05-31 1992-12-02 Eli Lilly And Company Vectors and methods for assaying the regulation of apolipoprotein ai synthesis
EP0519336A2 (en) * 1991-06-18 1992-12-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Chimeric gene comprising a promoter-regulater and a gene coding for an indicator protein
WO1994017208A1 (en) * 1993-01-21 1994-08-04 President And Fellows Of Harvard College Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
US5958707A (en) * 1991-10-03 1999-09-28 Schering Corporation Human interleukin-4 antagonist/agonist screens
WO2002052039A2 (en) * 2000-12-27 2002-07-04 Geneka Biotechnology Inc. Methods for selecting and producing pharmaceutical compounds using a library responsive to transcription factors
CN108707626A (en) * 2018-04-10 2018-10-26 中国科学院微生物研究所 A kind of preparation method of the monoclonal cell system of detectable pyrogen
CN111484980A (en) * 2020-03-18 2020-08-04 上海市食品药品检验所 Monoclonal cell strain, construction method thereof and application thereof in pyrogen assay

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0062237A1 (en) * 1981-03-25 1982-10-13 Yeda Research And Development Company, Ltd. Process for the determination of the carcinogenicity of chemical or physical agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0062237A1 (en) * 1981-03-25 1982-10-13 Yeda Research And Development Company, Ltd. Process for the determination of the carcinogenicity of chemical or physical agents

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, volume 101, no. 20, 12 November 1984, (Columbus, Ohio, US), Dinarello, Charles A et al : "Human leukocytic pyrogen test for detection of pyrogenic material in growth hormone produced by recombinant Escherichia coli ", see page 400, abstract 177607h, & J.Clin.Microbiol. 1984, 20( 3), 323- 32 *
Chemical Abstracts, volume 101, no. 26, 24 December 1984, (Columbus, Ohio, US), Henne, Werner et al : "Hollow-fiber dialyzers and their pyrogenicity testing by Limulus amebocyte lysate ", see page 305, abstract 235513n, & Artif.Organs 1984, 8( 3), 299- 30 *
Chemical Abstracts, volume 109, no. 15, 10 October 1988, (Columbus, Ohio, US), Karube, Isao et al : "Development of immuno-sensor system for determination of pyrogens ", see page 329, abstract 125177p, & Kenkyu Hokoku-Asahi Garasu Kogyo Gijutsu 1987, 51(), 301- 30 *
Chemical Abstracts, volume 111, no. 8, 21 August 1989, (Columbus, Ohio, US), Lee, Beom Jun et al : "Influence of low or high endotoxin-susceptible rabbit on pyrogen test ", see page 400, abstract 64042h, & Korean J. Toxicol. 1988, 4( 2), 181- 18 *
Chemical Abstracts, volume 96, no. 3, 18 January 1982, (Columbus, Ohio, US), Boobis, Susan et al : "Measurement of hypozincemia in mice:a sensitive test for detection of pyrogens ", see page 76, abstract 15678h, & Clin.Sci. 1981, 61( 4), 445- 44 *
Dialog Information Services, File 154, Medline 83- 90, Dialog accession no. 89137759, Poole S et al: "Assay of pyrogenic contamination in pharmaceuticalsby cytokine release from monocytes", Dev Biol Stand 1988, 69 p 121-3 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0496027A1 (en) * 1991-01-25 1992-07-29 R.O.B.I.T. RESEARCH AND DEVELOPMENT COMPANY LTD., c/o EFRATI, GALILI & CO. A bioluminescence assay for gene expression in growing mammalian cells
EP0516443A1 (en) * 1991-05-31 1992-12-02 Eli Lilly And Company Vectors and methods for assaying the regulation of apolipoprotein ai synthesis
EP0519336A2 (en) * 1991-06-18 1992-12-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Chimeric gene comprising a promoter-regulater and a gene coding for an indicator protein
EP0519336A3 (en) * 1991-06-18 1993-04-28 Boehringer Ingelheim International G.M.B.H. Chimeric gene comprising a promoter-regulater and a gene coding for an indicator protein
US5958707A (en) * 1991-10-03 1999-09-28 Schering Corporation Human interleukin-4 antagonist/agonist screens
US6200805B1 (en) 1991-10-03 2001-03-13 Schering Corporation Materials and methods for screening human interleukin-4 antagonists/agonists
US5811231A (en) * 1993-01-21 1998-09-22 Pres. And Fellows Of Harvard College Methods and kits for eukaryotic gene profiling
WO1994017208A1 (en) * 1993-01-21 1994-08-04 President And Fellows Of Harvard College Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
WO2002052039A2 (en) * 2000-12-27 2002-07-04 Geneka Biotechnology Inc. Methods for selecting and producing pharmaceutical compounds using a library responsive to transcription factors
WO2002052039A3 (en) * 2000-12-27 2004-02-19 Geneka Biotechnology Inc Methods for selecting and producing pharmaceutical compounds using a library responsive to transcription factors
CN108707626A (en) * 2018-04-10 2018-10-26 中国科学院微生物研究所 A kind of preparation method of the monoclonal cell system of detectable pyrogen
CN108707626B (en) * 2018-04-10 2021-10-01 中国科学院微生物研究所 Preparation method of monoclonal cell line capable of detecting pyrogen
CN111484980A (en) * 2020-03-18 2020-08-04 上海市食品药品检验所 Monoclonal cell strain, construction method thereof and application thereof in pyrogen assay

Also Published As

Publication number Publication date
IL93592A0 (en) 1990-12-23
CA2011799A1 (en) 1990-09-09
AU5160690A (en) 1990-10-09
GB8905394D0 (en) 1989-04-19

Similar Documents

Publication Publication Date Title
Heeger et al. Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes
Imler et al. A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum
Emmel et al. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
Weiss et al. Nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex
D'Alfonso et al. Systemic lupus erythematosus candidate genes in the Italian population: Evidence for a significant association with interleukin‐10
Umemori et al. Initial events of myelination involve Fyn tyrosine kinase signalling
Ahyi et al. IFN regulatory factor 4 regulates the expression of a subset of Th2 cytokines
Heyninck et al. The zinc finger protein A20 inhibits TNF-induced NF-κB–dependent gene expression by interfering with an RIP-or TRAF2-mediated transactivation signal and directly binds to a novel NF-κB–inhibiting protein ABIN
Murphy et al. Role of the Stat4 N domain in receptor proximal tyrosine phosphorylation
Jain et al. The AP-1 site at-150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter.
Srivastava et al. Estrogen blocks M-CSF gene expression and osteoclast formation by regulating phosphorylation of Egr-1 and its interaction with Sp-1.
Kim et al. TFII-I Enhances Activation of the c-fosPromoter through Interactions with Upstream Elements
KRUSE et al. The polymorphisms S503P and Q576R in the interleukin‐4 receptor α gene are associated with atopy and influence the signal transduction
Lütticken et al. Interleukin-6-induced serine phosphorylation of transcription factor APRF: evidence for a role in interleukin-6 target gene induction
Dong et al. The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression
Duncliffe et al. AT cell–specific enhancer in the interleukin-3 locus is activated cooperatively by Oct and NFAT elements within a DNase I–hypersensitive site
Brinkmann et al. Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus
Zhang et al. Regulation of the activity of IFN-γ promoter elements during Th cell differentiation
Li et al. Characterization of the human pleiotrophin gene. Promoter region and chromosomal localization.
Tsukada et al. A novel STAT-like factor mediates lipopolysaccharide, interleukin 1 (IL-1), and IL-6 signaling and recognizes a gamma interferon activation site-like element in the IL1B gene
Cockerill et al. Regulation of GM-CSF gene transcription by core-binding factor
Berberich‐Siebelt et al. C/EBPβ enhances IL‐4 but impairs IL‐2 and IFN‐γ induction in T cells
WO1990010710A1 (en) Detection of pyrogens by recombinant mammalian cells
Kim et al. The initiator element in a herpes simplex virus type 1 late-gene promoter enhances activation by ICP4, resulting in abundant late-gene expression
Shukla et al. Transforming growth factor beta increases the expression of HIV-1 gene in transfected human mesangial cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU FI HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE